World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
51983
World Ranking
6937
National Ranking
3654

Ruben A. Mesa publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ruben A. Mesa sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 879 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ruben A. Mesa D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ruben A. Mesa sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ruben A. Mesa is affiliated with The University of Texas Health Science Center at San Antonio in the United States. Their research primarily focuses on areas within medicine, with a notable emphasis on genetics, hematology, molecular biology, rheumatology, and oncology as subfields of study.

The scientist's work covers a range of topics, notably:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Kruppel-like factors research
  • Hemoglobinopathies and Related Disorders
  • Multiple Myeloma Research and Treatments

Ruben A. Mesa has contributed to several recent publications, including:

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, 2020, The Lancet
  • Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium, 2021, Annals of Oncology
  • Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer, 2021, Cancer Cell
  • The Impact of COVID-19 on Cancer Screening: Challenges and Opportunities, 2020, JMIR Cancer
  • Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study, 2023, The Lancet

The scientist frequently collaborates with several researchers, namely Claire Harrison, Srđan Verstovšek, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, and Stephen T. Oh. These collaborative relationships are reflected in multiple co-authored publications.

Ruben A. Mesa's work is prominently published in venues such as:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • HemaSphere
  • Journal of Clinical Oncology
  • Blood Advances

Their publication record indicates a strong focus on hematology and oncology-related research, with extensive contributions to myeloproliferative neoplasms and leukemia treatments. The integration of COVID-19-related cancer research within their recent works illustrates an engagement with emergent clinical challenges.

Best Publications

  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

    Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani

  • New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

    Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

    Alessandro M. Vannucchi;Jean Jacques Kiladjian;Martin Griesshammer;Tamas Masszi

  • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

    Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka

  • TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

    A. Tefferi;A. Pardanani;K. H. Lim;K. H. Lim;O. Abdel-Wahab

  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet

    Tiziano Barbui;Ayalew Tefferi;Alessandro M. Vannucchi;Francesco Passamonti

  • Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases

    Ruben A. Mesa;Chin Yang Li;Rhett P. Ketterling;Georgene S. Schroeder

  • The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

    Ruben A. Mesa;Joyce Niblack;Martha Wadleigh;Srdan Verstovsek

  • Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    Robyn M. Emanuel;Amylou C. Dueck;Holly L. Geyer;Jean Jacques Kiladjian

  • Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

    Animesh Pardanani;Claire Harrison;Jorge E. Cortes;Francisco Cervantes

  • Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

    Ruben A. Mesa;Murray N. Silverstein;Steven J. Jacobsen;Peter C. Wollan

  • Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

    G. Barosi;R. A. Mesa;J. Thiele;F. Cervantes

  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti

  • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

    Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi

  • The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients

    Robyn Scherber;Amylou C. Dueck;Peter Johansson;Tiziano Barbui

Frequent Co-Authors

Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Claire N. Harrison
Claire N. Harrison Guy's and St Thomas' NHS Foundation Trust
Amylou C. Dueck
Amylou C. Dueck Mayo Clinic
Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Francesco Passamonti
Francesco Passamonti University of Milan
Jason Gotlib
Jason Gotlib Stanford University
Francisco Cervantes
Francisco Cervantes University of Barcelona
Vikas Gupta
Vikas Gupta Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have more online opportunities than ever before. If you’re considering a career in healthcare but aren't set on becoming a doctor, there are flexible alternatives that allow you to study and work at the same time.

For those interested in leadership, healthcare administration degrees offer training in organizational management and health policy. Many are now available online, making it easier for working professionals to advance their careers.

Nurses seeking to upskill can explore bridge programs, such as the asn to np pathway. These programs support registered nurses who want to become nurse practitioners and often combine academic coursework with practical experience.

Nutrition is another growing field. Earning an online bachelor's degree in nutrition can open doors to roles in public health, counseling, and wellness coaching, all through fully online coursework.

For those ready to take on senior healthcare roles, cahme accredited online healthcare administration programs provide rigorous, industry-respected training for positions in hospital management, healthcare consulting, and beyond.

Best Scientists Citing Ruben A. Mesa

Trending Scientists

Recently Published Articles